First Biotech (Australia)

Company snapshot

Established in 1958, Beijing No.1 Biochemical Pharmaceutical Co. Ltd. is China’s first biochemical pharmaceutical company. It was affiliated to Peking University, but is now a separate and private entity. However it still works very closely with Peking University in many R&D projects. This company has been nominated as China’s National High-tech Enterprise by the government. The company is a Membe

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for First Biotech (Australia). Not investment advice.

• What is First Biotech (Australia)?

  Alcon Laboratories (Australia) is a pharma organization headquartered in AU. Primary therapeutic focus areas include Dry Eye Disease. NovaPharmaNews links 1 clinical program(s), 3 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and

• Is First Biotech (Australia) publicly traded?

  First Biotech (Australia) appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does First Biotech (Australia) develop or market?

  We link 4 drug profile(s) where First Biotech (Australia) is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/alcon-laboratories-u-k-limited#company-drugs.

• What are the latest developments for First Biotech (Australia)?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does First Biotech (Australia) focus on?

  First Biotech (Australia) focuses on Dry Eye Disease based on our analysis of their pipeline programs and drug development activities.